Eli Lilly and Company

Price Chart

Risk-Adjusted Performance

Also Listed On

Eli Lilly and Company (LLY) Price Performance

Eli Lilly and Company (LLY) trades on MX in MXN. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at MXN16221.00, down 2.49% from the previous close.

Over the past year, LLY has traded between a low of MXN11605.90 and a high of MXN20323.88. The stock has gained 7.4% over this period. It is currently 20.2% below its 52-week high.

Eli Lilly and Company has a market capitalization of $14.47T, with a price-to-earnings ratio of 1366.05 and a dividend yield of 71.00%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies; and Nimbus Therapeutics, LLC for the development of novel oral treatment for obesity and other metabolic diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.